Results of international clinical trial co-led by Peter Munk Cardiac Centre cardiologist Dr. Dinesh Thavendiranathan released.
While Canada has some of the best cancer survival rates in the world, many survivors have a heightened risk of developing heart disease because of their cancer treatment. Our very own Dr. Dinesh Thavendiranathan, Director of the Ted Rogers Cardiotoxicity Prevention Program and recent recipient of the Tier 2 Canada Research Chair, has laid out a series of objectives to improve patient outcomes. This includes immediate risk assessment for patients undergoing cancer treatment and novel detection and intervention methods to prevent heart-related side effects of cancer.
The results of an international clinical trial co-led by Dr. Thavendiranathan concluded that assessing deformation of heart muscle was a more advantageous indicator of heart damage than traditional methods, and that intervention following identification of damage led to a reduced risk of cardiotoxicity.
Watch Dr. Thavendiranathan explain the results of the trial and their impact below: